ClinicaliQ Trial Snapshot
- Endoscopic Submucosal Dissection for Early GI Neoplasia in the United Kingdom — Recruiting • Oncology • NCT03039309.
- What is being tested: Endoscopic submucosal dissection (ESD) effectiveness and safety as a treatment approach for early gastrointestinal neoplasia across multiple UK centres in a real-world cohort setting.
- Patient eligibility overview: The study includes patients with early GI neoplasia (including early gastric cancer, Barrett's oesophagus with high-grade dysplasia, and early colonic neoplasia) suitable for endoscopic management rather than surgical intervention.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Multicentre cohort study on the use of endoscopic submucosal dissection for the treatment of early gastrointestinal neoplasia.
Eligibility Snapshot
- : * Male or Female, aged 18 years or above undergoing endoscopic submucosal dissection * Participant is able to give informed consent for participation in the study
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.